tively low toxicity of the treatment led to a good quality of life and no need for prolonged hospitalization. Conclusion: To our knowledge, this is the first successful use of nilotinib in BCR-ABL1-like phenotype ALL. This case should encourage routine clinical use of molecular data to individualize therapies targeting the overexpressed pathways responsible for leukemic cell proliferation, as a means to overcome chemoresistance.
Introduction
Relapse after allogeneic hematopoietic cell transplantation (HCT) is a great challenge, especially in the case of acute lymphoblastic leukemia (ALL). Novel potentially effective treatment options include immunotherapy or chemo-immunotherapy (blinatumomab, inotuzumab), as well as experimental treatment with chi-
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Summary Introduction: Relapse of acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic cell transplantation (HCT) is a therapeutic challenge. We present the case of a 20-year-old patient with a relapse of Philadelphia chromosome-negative ALL B-common over 2 years after HCT with no response to salvage chemotherapy or blinatumomab, who finally responded to a molecularly tailored therapy adjusted to the BCR-ABL1-like phenotype. Methods: The BCR-ABL1-like phenotype was diagnosed on the basis of an increased expression of ABL1 and CRLF2 genes. Results: We combined a nilotinib-based therapy targeting the overexpressed ABL1 gene with a proteasome inhibitor and Peg-asparaginase, achieving a spectacular response: the percentage of lymphoblasts in the bone marrow was reduced from 70% to 5%, which enabled a second HCT to be performed. Moreover, the rela- meric antigen receptor T cells (CAR T cells) [1, 2] . Unfortunately, access to these therapies is very limited and results are not always satisfactory or long lasting. According to increasing knowledge concerning the molecular mechanisms driving leukemic transformation, the use of targeted molecules that block the pathways responsible for the disease's activity is very promising and proved to be very effective in Philadelphia chromosome (Ph)-positive ALL [3, 4] . Recently, analysis of gene expression and whole exome sequencing enabled identification of the subgroup of ALL with Ph-like (BCR-ABL1-like) phenotype presenting poor response to chemotherapy and unfavorable prognoses [5, 6] . The use of targeted molecules such as tyrosine kinase inhibitors (TKIs) could potentially improve the outcome [7, 8] . To our knowledge, this is the first described successful use of nilotinib in the setting of BCR-ABL1-like ALL.
Case Report
We present the case of a 20-year-old female patient with Ph(-) ALL B-common, initially treated with a high-risk ALLIC 2002 protocol, and subsequently allotransplanted according to an ALL-SCT-2009 protocol (TBI, Etoposide, ATG) from a matched unrelated donor (MUD). She relapsed 2 years and 8 months after HCT, with no remission after salvage therapy using HyperC-VAD/MA (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) and 2 courses of blinatumomab. In the meantime, another MUD was identified, and the patient was put on a list for therapy with CAR T cells in the United States.
Primary analysis of the gene expression revealed that leukemic cells might present a BCR-ABL1-like phenotype. Our patient was given a modified protocol for resistant ALL UK-ALL-R3 (mitoxantrone, vinblastine, L-asparaginase), combined with the wide-spectrum kinase inhibitor dasatinib to cover possible overexpressed kinases. Although the therapy was complicated due to a serious toxicity (bradycardia, left ventricular failure, bleeding from the gastro-intestinal tract) that forced us to discontinue dasatinib after 1 month, the peripheral blood (PB) parameters normalized, and the percentage of lymphoblasts in the bone marrow (BM) decreased from 97% to 50%.
Awaiting a CAR T cell therapy, the patient had only been receiving treatment for pulmonary aspergillosis, but after 4 months, a BM biopsy revealed increased lymphoblast infiltration (up to 70%). Armed with more precise data concerning overexpression of ABL1, another TKI nilotinib (800 mg/day), was introduced. Within 10 days of monotherapy with nilotinib, the blood parameters improved, and lymphoblasts in PB decreased from 11% to 2%. The treatment was extended to bortezomib (1.3 mg/m 2 on days 1, 4, 8, 11), dexamethasone (10-20 mg with bortezomib for 2 days) and PEG-asparaginase 1,000 units/ m 2 (1 dose per cycle). The dose of nilotinib was reduced to 400 mg due to hepatic toxicity, and bortezomib to 0.7 mg/m 2 due to neurotoxicity. After the first cycle, the lymphoblasts in the BM reduced to 20%, and after the following 3 courses to 7% ( fig. 1) . Despite an observed mild hematological toxicity, the patient did not require prolonged hospitalization and underwent the majority of the therapy in an out-patient manner.
Since the therapy with CAR T cells was no longer available, and the patient now qualified for HCT, a second HCT was performed with pre-planned post-HCT maintenance, using nilotinib and immunosuppression with sirolimus to target both overexpressed genes ABL1 and CRLF2. Prior to the transplant procedure, the percentage of blasts in the BM was 5% ( fig. 1) . Transplantation was performed with the use of a TBF (thiotepa, busulfan, fludarabine)-conditioning regimen. Granulocyte engraftment was achieved on day +17. The BM biopsy performed on day +30 revealed a complete remission (CR) with negative minimal residual disease and complete donor chimerism.
All the procedures and retrospective data analysis were conducted in accordance with the current version of the Declaration of Helsinki. Patient-identifying data were omitted to preserve the confidentiality of information. The blood samples for molecular analysis were collected with prior informed consent. The patient signed the necessary consent forms for the therapy.
Material and Methods
DNA and RNA were isolated from the mononuclear cells of the BM. 1 μg of total RNA was used for reverse transcription (RT). The RNA quality and quantity were assessed in relation to the GUS housekeeping gene. Subsequently Additionally, we used the multiplex ligation-dependent probe amplification (MLPA) method (MRC-Holland, SALSA MLPA P335 ALL-IKZF1 probe mix) to assess copy number alterations in the following genes: IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A-CDKN2B and the Xp22.33 region. To evaluate the CRLF2 and ABL1 overexpression, we used the 2-Ct method (relative to the PB from a healthy donor). Parallel RT-PCR was performed to detect dominantnegative IKZF1 isoforms.
The BCR-ABL1-like phenotype was diagnosed on the basis of CRLF2 (2-Ct = 837.53) and ABL1 (2-Ct = 240.52) gene overexpression ( fig. 2 ). The patient was negative for all analyzed fusion genes listed above, and JAK2 and IL7R mutations. The MLPA method revealed the presence of a heterozygous deletion of 4-8 exons in IKZF1, but with absent expression of dominantnegative IKZF1 isoforms.
Discussion
Most of the genetic abnormalities identified in BCR-ABL1-like phenotype ALL involve the genes encoding tyrosine kinases (ABL1/2, JAK1/2, PDGFRB, PDGFRA, SCF1R, and FLT3), the receptors activating tyrosine kinase JAK1/2 (EPOR and IL7R), or other molecules associated with tyrosine kinases and playing a role in the signal transduction pathways (CRLF2, SH2B3, and RAS) [6] . Certain pathways can be inhibited by molecular targeted agents such as TKIs (imatinib, dasatinib, nilotinib), a JAK1/2 inhibitor (ruxolitinib) or m-TOR inhibitors (e.g. sirolimus) [7, 9] . In the case of our patient, the phenotype was diagnosed on the basis of gene overexpression. Although no specific mutation was identified, it must have been located in the ABL1-activating gene and the response to TKIs clinically confirmed the significance of the ABL1 overexpression as the important leukemogenic pathway in this case. Nevertheless, we cannot exclude the significance of other unidentified mutations.
In a chemoresistant ALL relapse, the optimal scenario giving hope for a long-lasting remission was to achieve a second CR and to perform a second HCT. Using the results of molecular testing, we combined a TKI-based therapy with a proteasome inhibitor and Peg-asparaginase, achieving a spectacular response. Previously observed toxicity of combined chemotherapy with dasatinib discouraged us from re-using this agent. Aiming to achieve a better treatment tolerance as well as comparable efficacy, we decided to administer nilotinib: more selective than dasatinib and with a higher potency to block the ABL1 gene product in comparison to imatinib. The relatively low toxicity of the treatment with nilotinib led to a good quality of life and the patient was able to spend most of the treatment time with family. Therefore, on the basis of our experience and the available literature, we postulate the routine clinical use of molecular data to individualize therapies targeting the overexpressed pathways responsible for leukemic cells proliferation to overcome chemoresistance and improve the patient's outcome [1, 4, 7, 8, 10, 11] .
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